A study found that 1 in 8 patients thought to have epilepsy or unsure diagnosis actually had a heart rhythm issue causing fainting. Eighty percent of those who underwent pacemaker insertion were symptom-free after 9 months.
The PreSCD II registry found that patients protected by an implantable cardioverter defibrillator after a heart attack showed a non-significant lower mortality rate. In those with severely reduced heart function, mortality was reduced by 47% in patients with ICD implantation one month or more after MI.
A significant decline in heart attack mortality rates has been observed in Europe over the past 25 years, primarily due to organisational changes in the pre-hospital phase. The successful implementation of these measures can lead to a reperfusion rate of over 75% and reduce mortality to below 5%.
The PROTECT trial found that rolofylline had no significant effect on primary or secondary end-points in patients with acute heart failure, including dyspnea improvement and persistent renal impairment. The study did show an increased risk of neurological events in rolofylline-treated patients.
The survey enrolled 2438 patients with a mean age of 68 years, showing characteristic differences between those receiving CRT-P and CRT-D devices. Demographic and economic factors play a significant role in device selection, with younger patients, men, and those with ischaemic aetiology more likely to receive a CRT-D device.
The KYOTO HEART Study found that valsartan significantly reduced the incidence of cardiovascular events, including angina pectoris and stroke/TIA, in Japanese hypertensive patients. The study showed a lower rate of primary endpoints in the valsartan arm compared to non-ARB conventional therapies.
Researchers found that irbesartan reduced the risk of heart failure complications and a combination of stroke and other events by 13-14% in patients with atrial fibrillation. The study also showed significant reductions in hospitalizations for cardiovascular reasons and days spent in hospital.
Atrial fibrillation is a common cardiac arrhythmia affecting over 3 million Europeans, with high mortality rates. Treatment strategies include chronic antiarrhythmic drug therapy and catheter ablation, both effective but with varying side effects and success rates.
Currently only 1% of European patients with implantable cardiac devices are being remotely monitored. Telemonitoring reduces physician workload while maintaining patient safety through early detection of silent arrhythmias.
A recent study by the European Society of Cardiology found that public education on cardiac arrest could significantly improve survival rates among athletes. The study analyzed 700 sudden deaths during sport activity in France and found that bystander-initiated CPR increased hospital admission rates fourfold, while electric shock deliv...
A new trial aims to determine the best strategy for patients who cannot receive primary percutaneous coronary intervention (P-PCI) by investigating early fibrinolysis with mandated angiography. The study seeks to clarify whether this approach can achieve comparable outcomes to P-PCI.
Recent studies suggest that aspirin may not provide significant benefits for primary prevention in all diabetics. However, the European Society of Cardiology recommends its use for individuals with a high cardiovascular risk profile. Aspirin has been shown to reduce the risk of myocardial infarctions and strokes in this population, par...
The role of society in preventing chronic diseases such as CVD is crucial. Governments, industries, and civil society must collaborate to promote healthy lifestyles and environments. The impact of societal changes on health outcomes has been observed in countries like Finland, where CVD mortality has decreased by over 70%.
The new definition of syncope, including an aetiological requirement of reduced cerebral blood flow, provides a clearer picture of who and how many are affected by this common condition. The Guidelines identify three common types of syncope with different causes and risk profiles.
The TRIANA trial found primary angioplasty superior to thrombolysis in treating acute myocardial infarction (AMI) in patients aged 75 or older. Primary angioplasty showed a significantly lower need for recurrent cardiac ischemia and comparable outcomes compared to thrombolysis.
The new European Society of Cardiology guidelines update the treatment approach for infective endocarditis, emphasizing a multidisciplinary care team and earlier surgery. The guidelines also reduce antibiotic prophylaxis for high-risk dental procedures and highlight the importance of echocardiography in diagnosis and management.
The NORDISTEMI study found that patients in rural areas with long transfer delays experience improved treatment outcomes with thrombolysis followed by immediate angiography. The results suggest an early invasive strategy may be preferable to conservative management, reducing the risk of death, reinfarction, or stroke.
The guidelines focus on non-cardiac surgery, with an emphasis on assessing clinical risk factors and testing for ischaemic heart disease. Recommended medications include beta-blockers, statins, aspirin, and angiotensin converting enzyme inhibitors.
The ISAR-TEST-4 study found that biodegradable polymer drug-eluting stents are non-inferior to permanent polymer-based DES in preventing cardiac death, myocardial infarction, and revascularisation. The results indicate a comparable one-year clinical efficacy of the biodegradable polymer rapamycin-eluting stent.
A study of obese children found pre-diabetes, high blood pressure, and reduced HDL cholesterol levels, indicating impaired endothelial function. The degree of obesity correlated with vessel dysfunction, and self-healing capacity was compromised. These findings suggest a high risk of cardiovascular disease in young adults.
The GRACE registry study analyzed 43,018 ACS patients to determine the optimal revascularisation strategy for unprotected left main coronary disease. PCI is now the most common revascularisation strategy, preferred in higher-risk patients, while CABG is often delayed and associated with the best 6-month survival.
Two novel biomarkers, sensitive cardiac troponin assays and copeptin, significantly improve early detection of acute myocardial infarction. These markers enable doctors to diagnose AMI in the vast majority of patients presenting with chest pain, reducing complications and costs.
The PREDICT score identifies individual risk for poor responsiveness to clopidogrel through non-genetic factors. Studies show that response to clopidogrel is affected by genetic variants involving enzymes responsible for absorption and bio-activation of the medication.
A collaborative effort is needed to tackle cardiovascular disease (CVD) in Europe, focusing on lifestyle changes and risk factor management. The European Heart Health Charter has established a roadmap for countries, while guidelines from the Joint European Societies' Task Forces provide practical guidance.
The new guidelines identify six different clinical groups of pulmonary hypertension, with a focus on treatment strategies and risk stratification. Pulmonary arterial hypertension (group 1) is the only group provided with specific drug therapy and an evidence-based treatment algorithm.
Eating less red meat has been linked to reduced risk of cardiovascular disease and certain cancers. The World Health Organization recommends limiting weekly intake to 500 grams. By adopting this change, individuals can contribute to mitigating climate change and improving public health.
The PRAGUE-7 study, a randomized trial, investigated the effect of routine upfront administration of abciximab on outcomes in acute myocardial infarction (AMI) patients complicated by cardiogenic shock. The study found no significant benefit from this approach, with similar results seen between groups receiving standard or selective ab...
The Aspirin for Asymptomatic Atherosclerosis study found no statistically significant difference in primary endpoint events between those subjects allocated to aspirin or placebo. Vascular events and all-cause mortality were similar in both groups, but major bleeding occurred more frequently in the aspirin group.
The RE-LY study found dabigatran to be more effective than warfarin in preventing stroke in patients with atrial fibrillation. The higher dose of dabigatran significantly reduces stroke risk by 34% compared to warfarin, while the lower dose has a similar effect but with less major bleeding.
Recent discoveries of genetic variants affecting coronary artery disease and heart attack risk are promising for preventing the condition. The variants increase risk by 10-30% and are common, making them useful in prevention algorithms.
Studies suggest that raising hemoglobin levels with erythropoietin can improve exercise tolerance in heart failure patients. However, a large-scale trial is needed to determine if higher Hb targets are associated with adverse cardiovascular events.
A landmark international study found that high doses of clopidogrel significantly reduce stent thrombosis and heart attacks in patients undergoing angioplasty. The study showed a 30% reduction in stent thrombosis risk and a 22% lower risk of heart attack with the higher dose regimen.
The study reports on the short and mid-term outcomes of TAVI in 120 consecutive patients with severe symptomatic aortic stenosis, achieving a one-year survival rate of 79%. The most important predictor of late mortality was related to the learning curve, highlighting the necessity of proper training and high-volume centers.
30% of coronary heart disease and stroke can be prevented with 2.5 hours of brisk walking per week, reducing cardiovascular deaths by 284,886 annually. Regular exercise also improves glycemic control and insulin action, enhancing endothelial function.
A study found that high coffee consumption is associated with an increased risk of atrial fibrillation, a common arrhythmia. Patients with high caffeine intake and low Mediterranean diet adherence had higher rates of arrhythmias, suggesting a potential link between coffee consumption and cardiovascular disease.
The BARI 2D study found that diabetic patients with stable coronary artery disease benefit from a global care approach, combining medical management and revascularization strategies. A total of 42% of patients required revascularization within 5 years, highlighting the importance of comprehensive care.
Recent observational studies show no overall safety issue with drug eluting stents compared to bare metal stents, with lower risks of death or myocardial infarction. However, late stent thrombosis remains higher and uniquely associated with drug eluting stents, necessitating improved patient selection and treatment strategies.
A phase II trial shows otamixaban, an intravenous blood clot inhibitor, reduces major coronary complications in high-risk ACS patients with lower bleeding rates compared to heparin. The study found intermediate doses of otamixaban offer a significant reduction in death and ischemic complications.
The PLATO study demonstrated that ticagrelor reduced cardiovascular events by 16% compared to clopidogrel, with no increase in major bleeding. The efficacy of ticagrelor was observed across all major acute coronary syndromes patient types, with a consistent benefit seen in secondary endpoints.
The SYNTAX Trial interim analyses show CABG is superior to PCI in patients with severe coronary artery disease, especially those with diabetes. A multidisciplinary team approach is recommended for decision-making in complex CAD cases.
Smoking causes an estimated 0.7 million deaths per year in the European Union, with 23 years of life lost on average for those dying before age 70. Quitting smoking can reduce this risk, although a quarter of smokers will still die from tobacco-related causes if they continue
A recent analysis of 1.2 million Swedish hospital cases reveals that heart failure is associated with poor survival rates, more deaths, and premature life-years lost compared to common cancers. Heart failure affects more men and women than most cancer types, particularly in Sweden.
Concomitant kidney dysfunction and worsening renal function in heart failure patients are associated with a poor prognosis. New treatments target improving renal function and preventing its deterioration during hospitalizations for acute heart failure.
Two studies published in JAMA found that adopting a healthy lifestyle reduces lifetime risk of heart failure, with men who exercised regularly, drank moderately, and had a balanced diet having a lower risk. The studies also found an association between adherence to modifiable lifestyle factors and a significantly lower incidence of hyp...
A study found that a person's IQ explained over 20% of the difference in mortality between people from socio-economically disadvantaged backgrounds and those from more advantaged backgrounds. IQ was an additional factor to known risk factors like smoking and obesity.
The European Heart Rhythm Association recommends increasing remote monitoring of cardiovascular implantable electronic devices to enhance patient safety and reduce physician workload. This approach allows for immediate identification of device malfunctions and physiological changes, enabling timely interventions and cost-effective care.
The European Heart Rhythm Association's (EHRA) White Book reveals significant disparities in arrhythmia treatment across Europe. The book highlights differences in guideline implementation, trained physicians, and implantation rates, with some countries having no reimbursement for ICD or pacemaker therapy.
Patients with Implantable Cardioverter Defibrillators (ICDs) are at risk of sudden incapacitation while driving. A new consensus statement recommends driving restrictions based on the type of ICD and individual patient risk. The guidelines aim to balance patients' independence with safety concerns.
Long-term endurance sport participation increases the incidence of cardiac arrhythmias, particularly atrial fibrillation. Research efforts are focused on preventing and treating arrhythmias through techniques like CPVA and deconditioning.
Patients with both obesity and diabetes face a significantly worse prognosis, with effective treatment being